<DOC>
	<DOCNO>NCT01828736</DOCNO>
	<brief_summary>A multicenter , randomize , Phase 2 trial study effectiveness feasibility association trastuzumab combination chemotherapy advance metastatic bladder cancer patient . Combining monoclonal antibody therapy combination chemotherapy may improve treatment efficacy tumour overexpressed HER 2 .</brief_summary>
	<brief_title>Efficacy Combination Trastuzumab Gemcitabine - Platinum Advanced Metastatic Urothelial Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Transitional cell carcinoma urothelium bladder histologically proven stage IV AJCC [ locally advance ( T4b / N + M0 ) unresectable metastatic ( M1 ) ] Tumor / metastasis overexpressing HER2 immunohistochemistry ( IHC 3 + ) IHC 2 + FISH + . Centralized analysis . Measurable disease least one lesion diameter &gt; 2 cm conventional method ( clinical examination , CT MRI ) &gt; 1 cm helical scanner . In case single metastasis , metastatic disease histologically proven Age ≥ 18 year ≤80 year Life expectancy &gt; 3 month , Index performance status &lt; 2 accord ECOG PS , No prior chemotherapy adjuvant / neoadjuvant chemotherapy , without Herceptin ® complete 6 month ( naive previous chemotherapy metastatic setting ) No radiotherapy within 4 week prior inclusion , Normal cardiac function measure ejection fraction ( LVEF &gt; 50 % ) , Blood liver satisfactory constant : Hematological criterion : Neutrophils &gt; 1.5 x 109 / L , Chips &gt; 100 x 109 / L Hemoglobin &gt; 10 g / dL , Liver function : Alkaline phosphatase ( unless bone metastasis ) &lt; 2 x N Total bilirubin &lt; 1.5 x N transaminase ( AST , ALT ) &lt; 1.5 x N , renal Constants : Creatinine clearance &gt; 30 ml / min ( Cockcroft Gault , cf . Annex XV protocol ) Patient 's write consent full information . Concurrent treatment experimental drug , participation another clinical trial within &lt; 30 day Patients previously treat Herceptin ® , another treatment target growth factor EGF ( eg Iressa ® , Tarceva ® ) Existence severe pulmonary disease , liver kidney likely exacerbate treatment , Other medical condition : congestive heart failure angina pectoris even medically controlled failure , history myocardial infarction enter trial , hypertension uncontrolled arrhythmia , significant valvular disease , Patient dyspnoea rest require oxygen therapy respiratory failure , Presence severe infection require antibiotic , Presence CNS metastases meningeal History another malignancy uncured cure less 5 year ( except basal cell carcinoma , papillary thyroid carcinoma situ cervix treat ) Pregnant lactate use effective contraception Women , For Cisplatin : carry serious neurological disease , current event device &gt; NCI grade 2 neuropathy , hearing loss , creatinine clearance &lt; 60 ml / min , patient support patient hydration .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Urothelial carcinoma</keyword>
	<keyword>Trastuzumab</keyword>
	<keyword>Treatment</keyword>
</DOC>